Codetta Biosciences is building an integrated multi-omic platform combining reagents, hardware, and software to enable highly multiplexed, quantitative, simultaneous analysis of DNA, RNA, and protein. The company’s dsPCR and dsiPCR technologies target liquid biopsy and isolated nucleic acids and proteins, enabling detection of viral and bacterial targets, mutations, deletions, and gene and protein expression. Codetta positions its workflow as simple and sample-to-answer while delivering more high-quality data from a single specimen versus conventional technologies. The company plans to accelerate development of its multi-omic dsPCR platform and to aggressively scale its workforce across R&D, engineering, marketing, and business administration. Codetta describes its mission as advancing next-generation therapies by providing a simultaneous multi-omic dsPCR solution that improves research and clinical diagnostics. The company is based in Research Triangle Park, North Carolina.

Total raised

$15M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2022